A potential drug interaction between phenobarbital and dolutegravir: A case report

J Infect Chemother. 2018 Jun;24(6):476-478. doi: 10.1016/j.jiac.2017.12.022. Epub 2018 Feb 4.

Abstract

In this report, we describe a human immunodeficiency virus (HIV)-infected patient in whom changes in phenobarbital (PB) dosage resulted in associated changes in plasma concentrations of dolutegravir (DTG). His plasma concentrations of DTG were 0.934, 0.584, 1.003 and 3.25 μg/mL, respectively, with concomitant daily PB doses of 40, 70, 30 and 0 mg, respectively. This case suggests that PB can lead to a remarkable reduction in the plasma concentration of DTG in a dose-dependent manner.

Keywords: Dolutegravir; Dose-dependent; Interaction; Phenobarbital.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Retroviral Agents / administration & dosage*
  • Anti-Retroviral Agents / blood
  • Anti-Retroviral Agents / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Therapy, Combination
  • HIV Infections / drug therapy*
  • HIV Integrase Inhibitors / administration & dosage
  • HIV Integrase Inhibitors / blood*
  • HIV Integrase Inhibitors / therapeutic use
  • Heterocyclic Compounds, 3-Ring / administration & dosage
  • Heterocyclic Compounds, 3-Ring / blood*
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Male
  • Oxazines
  • Phenobarbital / administration & dosage*
  • Phenobarbital / blood
  • Phenobarbital / therapeutic use
  • Piperazines
  • Pyridones

Substances

  • Anti-Retroviral Agents
  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir
  • Phenobarbital